Progress in pathological diagnosis and neoadjuvant therapy evaluation of esophageal cancer
10.3760/cma.j.cn101721-20240318-00076
- VernacularTitle:食管癌的病理诊断及新辅助治疗评估进展
- Author:
Jiting DI
1
;
Yan XIONG
Author Information
1. 北京大学第一医院病理科，北京 100034
- Keywords:
Esophageal cancer;
Pathological diagnosis;
Pathophysiological changes;
Neoadjuvant therapy evaluation
- From:
Clinical Medicine of China
2024;40(4):254-258
- CountryChina
- Language:Chinese
-
Abstract:
Esophageal cancer is one of the common diseases that threaten human health, with high morbidity and mortality. The main histological types are squamous cell carcinoma and adenocarcinoma, both of which have unique pathophysiological changes, major risk factors, epidemiological characteristics and morphological changes. Most patients are locally advanced at the first visit, and neoadjuvant combined surgery has become the standard treatment for these patients. After neoadjuvant therapy, residual tumor cells in surgical resection specimens are related to prognosis. Pathologists need to understand the histopathological changes of esophageal cancer after neoadjuvant therapy and conduct a comprehensive and standardized evaluation of the degree of tumor regression to provide valuable prognostic information and guide further treatment.
